[The last few years have seen an increasingly widespread use of anticoagulant treatment. Not only is it applied in a wider range of diseases, but the duration of the treatment has also become longer on the basis of recent recommendations. Beside the traditional anticoagulant agents, coumarin and heparin, a new generation of anticoagulants has emerged in the past few years. These can be administered orally in a fixed dose, which will make anticoagulant treatment available for an even wider patient population. However, the more widespread use of anticoagulants will result in the growing occurrence of their most threatening adverse effect, bleeding. We summarize the treatment options for the bleeding complications in connection with the administration of the currently used anticoagulants and the available methods of their reversal.]

[INTRODUCTION - Micafungin is a new member of the antifungal class echinocandin exhibiting a broad-spectrum activity against Candida spp. MATERIAL AND METHODS - In this study, we collected 246 invasive clinical Candida isolates obtained from 4 diverse medical centers between 01.04.2009 and 01.04.2010. In these isolates we determined the minimum inhibitory concentrations (MIC) of micafungin. RESULTS - Among the 246 isolates 156 (62%) were C. albicans, 26 (11%) C. glabrata, 24 (10%) C. parapsilosis, 16 (7%) C. krusei, 14(6%) C. tropicalis and 10 (4%) other, less frequently isolated Candida spp. Micafungin had good in vitro activity against all Candida spp. tested (except C. parapsilosis), MIC90 range 0,016-0,125 mg/L. According to CLSI criteria, all isolates (except C. parapsilosis MIC90 2 mg/L) can be interpreted as susceptible. CONCLUSIONS - In vitro MIC90 values measured in this study were substantially lower than the maximum serum concentrations that can be achieved after administration of micafungin (8 mg/L after a 75-mg dose). This fact and the fungicid effect of micafungin against Candida species make this compound, which is licenced for the treatment of invasive candidiasis, a promising systemic antifungal agent.]